Investors wiped some 6 billion euros ($7.97 billion) off the market value of French pharmaceutical company Sanofi-Aventis Thursday after U.S. federal health advisers rejected its Accomplia weight-loss drug.
The Food and Drug administration's advisory panel rejected the drug, also known as rimonabant and Ziumlti, after hearing testimony that it increases the risk of suicidal thoughts, even in patients with no history of depression.